Who are Haloperidol Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone and Ramelteon, placebo with Clozapine, Standard of Care Oral antipsychotics, Methylphenidate, aripiprazole, and combination, Intramuscular olanzapine, aripiprazole, OBR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/haloperidol-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Haloperidol Injection — Competitive Intelligence Brief

Haloperidol Injection (Haloperidol Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: First-generation antipsychotic (typical antipsychotic). Area: Psychiatry.

marketed First-generation antipsychotic (typical antipsychotic) Dopamine D2 receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Haloperidol Injection (Haloperidol Injection) — Hennepin Healthcare Research Institute. Haloperidol blocks dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission to treat psychotic symptoms and agitation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Haloperidol Injection TARGET	Haloperidol Injection	Hennepin Healthcare Research Institute	marketed	First-generation antipsychotic (typical antipsychotic)	Dopamine D2 receptor
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
placebo with Clozapine	placebo with Clozapine	Shanghai Mental Health Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Standard of Care Oral antipsychotics	Standard of Care Oral antipsychotics	University of Utah	marketed	Antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor
Methylphenidate, aripiprazole, and combination	Methylphenidate, aripiprazole, and combination	Tri-Service General Hospital	marketed	Stimulant and atypical antipsychotic combination	Dopamine transporter (DAT), norepinephrine transporter (NET), dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor
Intramuscular olanzapine, aripiprazole	Intramuscular olanzapine, aripiprazole	Veterans Medical Research Foundation	marketed	Atypical antipsychotic	Dopamine D2 receptor; serotonin 5-HT2A receptor (olanzapine); dopamine D2 partial agonist (aripiprazole)
OBR	OBR	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic (depot formulation)	Dopamine D2 receptor (partial agonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (First-generation antipsychotic (typical antipsychotic) class)

Hennepin Healthcare Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Haloperidol Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/haloperidol-injection. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab